Corline Biomedical AB (CLBIO) — Cash Flow Reinvestment Rate

Latest as of March 2024: 1.60x

Corline Biomedical AB (CLBIO) has a Cash Flow Reinvestment Rate of 1.60x as of March 2024, reinvesting Skr3.67 Million (capex Skr1.83 Million plus investments Skr-1.83 Million) from operating cash flow of Skr2.30 Million. Explore CLBIO capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.60x
(Capex + Investments) / Operating CF

Total Reinvested

Skr3.67 Million
Capex + Investments

Operating Cash Flow

Skr2.30 Million
SEK

Capital Expenditures

Skr1.83 Million
SEK

Corline Biomedical AB Cash Flow Reinvestment Rate (2023–2023)

Historical reinvestment intensity for Corline Biomedical AB across 1 annual periods. Also explore CLBIO total asset value for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Corline Biomedical AB (2023–2023)

Year-by-year capital reinvestment analysis for Corline Biomedical AB. For live market cap and broader valuation context, see how much is Corline Biomedical AB worth.

Year Reinvestment Rate Total Reinvested (SEK) Operating CF Capex YoY Change
2023 23.23x Skr20.59 Million Skr886.00K Skr10.62 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow